Canagliflozin
INVOKANA
SGLT2 Inhibitor (Antidiabetic)
NADAC/unit
$19.1063
No Shortage
INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular eve....
vs. brand INVOKANA: Generic saves up to -91% per unit
Generic Manufacturers
JANSSEN PHARMACEUTICALS INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.